UNSPSC 51123707: Bunaftine citrate

This classification denotes an antiarrhythmic agent with the molecular formula C21H30N2O.C6H8O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0A2V53992Z. The term bunaftine citrate is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule bunaftine citrate under HS 29242995. As of Q4 2014, BUNAFTINE CITRATE remains US FDA's Preferred Term for this commodity. SMILES: CCCCN(CCN(CC)CC)C(=O)C1CCCC2C1CCCC2.C(C(=O)O)C(CC(=O)O)(C(=O)O)O.

UNSPSC 51123707 Bunaftine citrate is a Commodity code representing pharmaceutical active ingredients and finished medications procured by state and local government agencies for emergency medical services, institutional healthcare, and pharmacy benefit programs. State and local governments buy specific medications under this code to support fire rescue operations, emergency life support protocols, and broader pharmacy benefit initiatives; recent solicitations show demand for advanced life support medications, generic pharmaceuticals, and over-the-counter products sourced through established wholesale distribution channels and direct-to-manufacturer arrangements. Issuing bodies include municipal purchasing departments (the City of Tampa's Purchasing Department), state health and human services agencies (Texas Health and Human Services Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, serving participating state and local government facilities across multiple jurisdictions including Minnesota and Oregon). The scope of work spans sealed competitive bidding for specific medication line items with strict expiration and shelf-life requirements, multi-vendor RFPs establishing framework agreements for generic pharmaceutical supply chains with authorized wholesalers, and exploratory RFIs to evaluate direct-to-manufacturer prescription program capabilities.

Recent activity concentrates in Florida, Texas, and Minnesota, with MMCAP's cooperative model extending reach across Oregon and other participating jurisdictions. The City of Tampa issued IFB 26P00188 (due April 8, 2026) for Advanced Life Support Medications—370 units of Labetalol HCI 100mg vials, 1,810 units of Epinephrine 1:10,000 injections, 330 units of Adenosine 6mg vials, and 1,020 units of Diltiazem 25mg vials for Tampa Fire Rescue, with an estimated contract value of $40,000.00, a one-year term with two one-year renewal options, and a 5 percent bid discount for Small Local Business Enterprise participation. The Texas HHS Commission issued RFI HHS0017013 (response deadline April 3, 2026) to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information on direct contracting capacity, negotiated net pricing models, and outcomes-based agreement implementation to inform future RFP development. MMCAP's RFP S1070000015802 (due March 26, 2026) sought manufacturers of generic multi-source pharmaceuticals and OTC products for distribution through AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., with contract effectiveness July 1, 2026, a two-year initial term, mandatory cGMP and DSCSA compliance, and a 3 percent administrative fee on all purchases.